Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to determine the safety and efficacy of Pegasys + placebo + lamivudine versus lamivudine alone in patients with lamivudine versus lamivudine alone in patients with hepatitis B antigen CHB.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| PEGASYS | Drug |
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Scottsdale | Arizona | 85259 | United States | |||
Not provided
Not provided
Not provided
Not provided
Not provided
| Downey |
| California |
| 90242 |
| United States |
| Los Angeles | California | 90048 | United States |
| Pasadena | California | 91105 | United States |
| San Francisco | California | 94115 | United States |
| Atlanta | Georgia | 30308 | United States |
| Honolulu | Hawaii | 96817 | United States |
| Boston | Massachusetts | 02111 | United States |
| Ann Arbor | Michigan | 48109 | United States |
| Minneapolis | Minnesota | 55404-4565 | United States |
| Lincoln | Nebraska | 68501 | United States |
| Chapel Hill | North Carolina | 27599-7080 | United States |
| Cedar Creek | Texas | 78612 | United States |
| Salt Lake City | Utah | 84121 | United States |
| Seattle | Washington | 98195 | United States |
| Concord | 2139 | Australia |
| Herston | 4029 | Australia |
| Campinas | 13081-970 | Brazil |
| Porto Alegre | 90035-003 | Brazil |
| Salvador | 40150-130 | Brazil |
| São Paulo | 01246-900 | Brazil |
| Calgary | Alberta | T2N 4N1 | Canada |
| Toronto | Ontario | M5G 1L7 | Canada |
| Toronto | Ontario | M5G 1X5 | Canada |
| Beijing | 100011 | China |
| Beijing | 100034 | China |
| Beijing | 100039 | China |
| Beijing | 100050 | China |
| Beijing | 100054 | China |
| Chengdu | 610041 | China |
| Chongqing | 400010 | China |
| Guangzhou | 510515 | China |
| Guangzhou | 510630 | China |
| Hangzhou | 310003 | China |
| Hong Kong | China |
| Shanghai | 200025 | China |
| Shanghai | 200040 | China |
| Shanghai | 200433 | China |
| Clichy | 92110 | France |
| Lyon | 69288 | France |
| Berlin | 13353 | Germany |
| Bochum | 44791 | Germany |
| Cologne | 50931 | Germany |
| Düsseldorf | 40225 | Germany |
| Hanover | 30623 | Germany |
| München | 81377 | Germany |
| Haifa | 31096 | Israel |
| Petah Tikva | 49100 | Israel |
| Tel Aviv | 64239 | Israel |
| Otahuhu | New Zealand |
| Bialystok | 15-540 | Poland |
| Bydgoszcz | 85-030 | Poland |
| Warsaw | 01-201 | Poland |
| Santurce | 00909 | Puerto Rico |
| Singapore | 159402 | Singapore |
| Singapore | 169608 | Singapore |
| Singapore | 228510 | Singapore |
| Seoul | 120-752 | South Korea |
| Seoul | 135-170 | South Korea |
| Seoul | 138-736 | South Korea |
| Seoul | 150-713 | South Korea |
| Basel | 4031 | Switzerland |
| Kaohsiung City | Taiwan |
| Kwei Shan | Taiwan |
| Tainan | Taiwan |
| Taipei | 100 | Taiwan |
| Taipei | 114 | Taiwan |
| Taipei | Taiwan |
| Bangkok | 10330 | Thailand |
| Bangkok | 10400 | Thailand |
| Bangkok | 10700 | Thailand |
| Chiang Mai | 50202 | Thailand |
| Songkhla | 90112 | Thailand |
| Nottingham | NG2 3HF | United Kingdom |
| ID | Term |
|---|---|
| D019694 | Hepatitis B, Chronic |
| ID | Term |
|---|---|
| D006509 | Hepatitis B |
| D000086982 | Blood-Borne Infections |
| D003141 | Communicable Diseases |
| D007239 | Infections |
| D018347 | Hepadnaviridae Infections |
| D004266 | DNA Virus Infections |
| D014777 | Virus Diseases |
| D006525 | Hepatitis, Viral, Human |
| D006521 | Hepatitis, Chronic |
| D006505 | Hepatitis |
| D008107 | Liver Diseases |
| D004066 | Digestive System Diseases |
| D002908 | Chronic Disease |
| D020969 | Disease Attributes |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
Not provided
Not provided
| ID | Term |
|---|---|
| C100416 | peginterferon alfa-2a |
Not provided
Not provided
Not provided